Eli Lilly (NYSE:LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday.  The ...

Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for ...

Now the question is: Is it too late to get in on this weight loss giant, or is Lilly stock still a buy? Let's find out. So, first let's talk about the Eli Lilly story so far. It's important to ...

or is Lilly stock still a buy? Let's find out. Image source: Getty Images. What's behind Lilly's double-digit revenue growth So, first let's talk about the Eli Lilly story so far. It's important ...